NewAmsterdam Pharma (NAMS) Competitors $26.58 -0.16 (-0.58%) As of 02:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NAMS vs. RDY, QGEN, BBIO, MRNA, VRNA, ELAN, ROIV, RVMD, GRFS, and RYTMShould you be buying NewAmsterdam Pharma stock or one of its competitors? The main competitors of NewAmsterdam Pharma include Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Grifols (GRFS), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry. NewAmsterdam Pharma vs. Its Competitors Dr. Reddy's Laboratories QIAGEN BridgeBio Pharma Moderna Verona Pharma PLC American Depositary Share Elanco Animal Health Roivant Sciences Revolution Medicines Grifols Rhythm Pharmaceuticals NewAmsterdam Pharma (NASDAQ:NAMS) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation. Which has stronger earnings & valuation, NAMS or RDY? Dr. Reddy's Laboratories has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNewAmsterdam Pharma$45.56M65.70-$241.60M-$1.62-16.40Dr. Reddy's Laboratories$3.81B3.27$663M$0.6622.64 Do institutionals and insiders believe in NAMS or RDY? 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 20.8% of NewAmsterdam Pharma shares are owned by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, NAMS or RDY? NewAmsterdam Pharma has a beta of -0.01, suggesting that its share price is 101% less volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Does the media prefer NAMS or RDY? In the previous week, NewAmsterdam Pharma had 3 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 9 mentions for NewAmsterdam Pharma and 6 mentions for Dr. Reddy's Laboratories. NewAmsterdam Pharma's average media sentiment score of 1.38 beat Dr. Reddy's Laboratories' score of 1.01 indicating that NewAmsterdam Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is NAMS or RDY more profitable? Dr. Reddy's Laboratories has a net margin of 16.99% compared to NewAmsterdam Pharma's net margin of -259.07%. Dr. Reddy's Laboratories' return on equity of 17.25% beat NewAmsterdam Pharma's return on equity.Company Net Margins Return on Equity Return on Assets NewAmsterdam Pharma-259.07% -27.27% -25.00% Dr. Reddy's Laboratories 16.99%17.25%11.63% Do analysts prefer NAMS or RDY? NewAmsterdam Pharma currently has a consensus target price of $41.55, indicating a potential upside of 56.33%. Dr. Reddy's Laboratories has a consensus target price of $16.95, indicating a potential upside of 13.42%. Given NewAmsterdam Pharma's stronger consensus rating and higher probable upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Dr. Reddy's Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewAmsterdam Pharma 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Dr. Reddy's Laboratories 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.80 SummaryDr. Reddy's Laboratories beats NewAmsterdam Pharma on 9 of the 17 factors compared between the two stocks. Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NAMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAMS vs. The Competition Export to ExcelMetricNewAmsterdam PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.00B$2.56B$5.77B$10.40BDividend YieldN/A57.29%5.74%4.64%P/E Ratio-16.4222.7777.0926.80Price / Sales65.70550.93494.34162.00Price / CashN/A169.7137.1760.63Price / Book3.245.3713.816.41Net Income-$241.60M$32.95M$3.29B$271.62M7 Day Performance9.86%1.40%1.20%2.96%1 Month Performance8.69%7.46%6.49%9.80%1 Year Performance65.47%-2.85%81.94%31.48% NewAmsterdam Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAMSNewAmsterdam Pharma3.3149 of 5 stars$26.58-0.6%$41.55+56.3%+67.6%$3.00B$45.56M-16.424Positive NewsRDYDr. Reddy's Laboratories2.3933 of 5 stars$14.27-0.5%$16.95+18.8%-6.0%$11.97B$3.81B21.6127,811Positive NewsQGENQIAGEN4.4603 of 5 stars$47.62+0.1%$49.69+4.4%+3.0%$10.57B$1.98B28.135,765Positive NewsBBIOBridgeBio Pharma4.289 of 5 stars$54.29+1.7%$63.35+16.7%+105.4%$10.20B$221.90M-13.27400MRNAModerna4.5441 of 5 stars$24.83-1.2%$42.88+72.7%-63.6%$9.78B$3.24B-3.305,800VRNAVerona Pharma PLC American Depositary Share2.1751 of 5 stars$106.300.0%$109.00+2.5%+263.5%$9.20B$42.28M-107.3730Positive NewsELANElanco Animal Health2.8613 of 5 stars$19.02+3.2%$17.33-8.9%+30.5%$9.16B$4.44B22.129,000Positive NewsROIVRoivant Sciences3.4941 of 5 stars$12.91-0.1%$16.38+26.8%+25.8%$8.82B$29.05M-18.44860Trending NewsAnalyst ForecastRVMDRevolution Medicines4.2794 of 5 stars$41.06+1.4%$72.00+75.4%+2.6%$7.57B$11.58M-9.12250Positive NewsInsider TradeGRFSGrifols3.8378 of 5 stars$10.11-0.2%$10.30+1.9%+12.4%$6.96B$7.81B8.6423,822RYTMRhythm Pharmaceuticals3.2463 of 5 stars$99.77-2.3%$101.57+1.8%+83.7%$6.78B$130.13M-33.15140Positive News Related Companies and Tools Related Companies Dr. Reddy's Laboratories Alternatives QIAGEN Alternatives BridgeBio Pharma Alternatives Moderna Alternatives Verona Pharma PLC American Depositary Share Alternatives Elanco Animal Health Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives Grifols Alternatives Rhythm Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NAMS) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Company N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
